Review Article
Lipid Nanoparticles as Carriers for RNAi against Viral Infections: Current Status and Future Perspectives
Table 3
Studies carried out with lipid-based nanosystems as RNAi delivery vectors against hepatitis B (HBV).
| Lipid nanosystem | RNAi | Targeting molecule | Culture cells | In vivo model | Reference |
| SNALP | HBV siRNAs chemically stabilized for nuclease resistance | — | HBV-replicating HepG2 | HBV mouse model constructed by hydrodynamic injection of HBV vector DNA | [47] | Cationic liposomes | HBV-X specific siRNA (siHBV) | Apo A-I | HepG2 and Huh7 | Acute HBV-infected mouse model by hydrodynamic injection of a plasmid | [48] | PEGylated cationic liposomes | HBV specific siRNA | — | Huh7 cells previously transfected with HBV replication target plasmid | HBV transgenic mice | [49] | DODAG 8 lipid | HBV specific siRNA | — | — | HBV transgenic mice | [50] | Cationic liposomes | Altriol modified HBV-X siRNA | Galactose | Huh7 cells previously transfected with HBV target DNA plasmid | HBV transgenic mice | [51] |
|
|
SNALP: stable nucleic acid lipid particle; HepG2: liver hepatocellular carcinoma cells; HuH7: human hepatoma cell line; DODAG: , -dioctadecyl-N-4,8- diaza-10-aminodecanoylglycine amide.
|